Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
For cancer patients undergoing chemotherapy adverse reactions are part and parcel of the treatment. Previous studies have shown that patients who have adverse effects early on (within one week) have better response to the treatment. This study looks at PARPi treatment for ovarian cancer and notes a similar outcome.
PARPi drugs are a targeted chemotherapy for ovarian cancer patients. Most if not all patients taking PARPi drugs have adverse effects. 10-15% of the patients cannot complete the course due to significant toxicity, with marrow suppression, nausea, and fatigue being common.
Results from this small prospective study (78 women) confirmed that an early adverse response did improve the outcome. In addition those women who developed anaemia during the first 4 weeks of treatment, suggesting marrow suppression, had better progress free survival, with a median of 30 weeks compared to 20 weeks for those not anaemic.
No comments:
Post a Comment